Filing Flows › Companies › Expedia Group › Timeline
Expedia Group stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+18.9% to $259.24
Expedia Group (EXPE) stock rose 19% over the last 252 sessions, to $259.24. On the way it reported 5 quarters, its insiders filed 5 open-market trades and 4 Form 144 notices of planned sales, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 9, 2026 | Form 144 | Form 144: Robert Dzielak plans to sell $4.8M | — | — | — |
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 5.7% | +10.0% (+8.4% vs SPY) | — | — |
| Aug 24, 2026 | Insider sale | Dzielak Robert J sold $336K | +5.3% (+5.6% vs SPY) | +2.6% (+2.1% vs SPY) | −13.5% (−14.7% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: Lance Soliday plans to sell $909K | +0.9% (+1.6% vs SPY) | +6.3% (+7.5% vs SPY) | −10.3% (−7.8% vs SPY) |
| Aug 18, 2026 | Insider sale | Soliday Lance A sold $909K | +0.9% (+1.6% vs SPY) | +6.3% (+7.5% vs SPY) | −10.3% (−7.8% vs SPY) |
| Aug 17, 2026 | Insider sale | Dzielak Robert J sold $661K | −4.4% (−3.9% vs SPY) | −3.4% (−2.0% vs SPY) | −12.5% (−10.0% vs SPY) |
| Aug 13, 2026 | Form 144 | Form 144: Craig A Jacobson plans to sell $1.0M | +0.8% (+0.1% vs SPY) | +0.2% (+0.7% vs SPY) | −14.6% (−13.6% vs SPY) |
| Aug 13, 2026 | Insider sale | Jacobson Craig A sold $1.0M | +0.8% (+0.1% vs SPY) | +0.2% (+0.7% vs SPY) | −14.6% (−13.6% vs SPY) |
| Aug 11, 2026 | Insider sale | Dzielak Robert J sold $946K | +2.2% (+2.5% vs SPY) | +1.4% (+1.5% vs SPY) | −14.0% (−12.6% vs SPY) |
| Aug 10, 2026 | Form 144 | Form 144: Robert Dzielak plans to sell $1.8M | +1.1% (+1.1% vs SPY) | +6.9% (+6.5% vs SPY) | −12.2% (−11.3% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: beat the EPS estimate by 9.7% | +2.4% (+2.6% vs SPY) | +2.9% (+3.0% vs SPY) | −1.1% (−0.3% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 42.3% | +2.5% (+2.8% vs SPY) | −12.6% (−13.7% vs SPY) | −7.3% (−7.8% vs SPY) |
| Apr 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | −5.5% (−5.1% vs SPY) | −5.4% (−5.5% vs SPY) | −19.3% (−23.6% vs SPY) |
| Mar 30, 2026 | 8-K | Material definitive agreement | +1.9% (−1.0% vs SPY) | −1.0% (−5.2% vs SPY) | +10.1% (−1.7% vs SPY) |
| Feb 12, 2026 | Earnings | Earnings: beat the EPS estimate by 12.2% | −2.8% (−1.2% vs SPY) | −15.7% (−14.6% vs SPY) | −2.0% (+2.4% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 9.0% | +2.7% (+3.8% vs SPY) | +24.7% (+23.8% vs SPY) | +21.1% (+19.9% vs SPY) |
Insiders’ record here
In the year on the chart, Expedia Group's insiders reported 0 open-market buys ($0) and 5 sales ($3.9M).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Expedia Group: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.